Generic filters
Filter by content type
Taxonomy terms

CNTA – Centessa Pharmaceuticals PLC


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 6

Low: 4

High: 11

Total Analysts: 4

Company Profile

Centessa Pharmaceuticals plc (Centessa), formerly Centessa Pharmaceuticals Limited, is a pharmaceutical company. The Company’s asset-centric programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. Its portfolio consists of approximately 16 conviction programs, including four programs evaluated in clinical trials and 12 additional preclinical programs. Centessa’s clinical stage product candidates include Lixivaptan, SerpinPC, Imgatuzumab and ZF874. The Company’s preclinical assets include ZF887, MGX292, CBS001, CBS004, LB1, LB2, Oral OX2R Agonist, Intranasal OX2R Agonist, Dual STAT3/5 Degrader, EGFR Ex20 Inhibitor, EGFR-C797S Inhibitor and EGFR Inhibitors. The Company’s subsidiaries include ApcinteX, Capella BioScience, Janpix, LockBody, Morphogen-IX, Orexia Therapeutics, Palladio Biosciences, PearlRiver Bio, PegaOne and Z Factor.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan